Our analysis confirmed that TLR5 agonist monotherapy could attenuate the proliferation of MC-38 colorectal cancer cells, suggesting that treatment with a TLR5 agonist alone triggers an anti-tumor immune response against colorectal cancer. This evidence concerns the gene TLR5 and neoplasm.